QuickStripe™ Hepatitis B

A rapid test for the qualitative detection of Hepatitis B Surface Antigen (HBsAg) in serum or plasma.

**Instruction Manual**

**Test kit for 20 tests individually pouched**
(Catalog No. 41104)

**For In Vitro Diagnostic Use**
For professional use only

**Store at 2-30°C. Do Not Freeze**

Savyon® Diagnostics Ltd.
3 Habosem St. Ashdod 77610
ISRAEL
Tel.: +972.8.8562920
Fax: +972.8.8523176
E-mail: support@savyondiagnostics.com

**Intended Use**

The QuickStripe™ Hepatitis B is a rapid chromatographic immunoassay for the qualitative detection of Hepatitis B Surface Antigen in serum or plasma.

**Summary**

Viral hepatitis is a systemic disease primarily involving the liver. Most cases of acute viral hepatitis are caused by Hepatitis A virus, Hepatitis B virus (HBV) or Hepatitis C virus. The complex antigen found on the surface of HBV is called HBsAg. Previous designations included the Australia or Au antigen. The presence of HBsAg in serum or plasma is an indication of an active Hepatitis B infection, either acute or chronic. In a typical Hepatitis B infection, HBsAg will be detected 2 to 4 weeks before the ALT level becomes abnormal and 3 to 5 weeks before symptoms or jaundice develop. HBsAg has four principal subtypes: adw, ayr, ad and ayr. Because of antigenic heterogeneity of the determinant, there are 10 major serotypes of Hepatitis B virus.

The QuickStripe™ Hepatitis B is a rapid test to qualitatively detect the presence of HBsAg in serum or plasma specimen. The test utilizes a combination of monoclonal and polyclonal antibodies to selectively detect elevated levels of HBsAg in serum or plasma.

**Principle**

The QuickStripe™ Hepatitis B is a qualitative, lateral flow immunoassay for the detection of HBsAg in serum or plasma. The membrane is pre-coated with anti-HBsAg antibodies on the test line region of the test. During testing, the serum or plasma specimen reacts with the particle coated with anti-HBsAg antibody. The mixture migrates upward on the membrane chromatographically by capillary action to react with anti-HBsAg antibodies on the membrane and generate a colored line. The presence of this colored line in the test region indicates a positive result, while its absence indicates a negative result. To serve as a procedural control, a colored line will always appear in the control line region indicating that proper volume of specimen has been added and membrane wicking has occurred.

**Reagents**

The test device contains anti-HBsAg particles and anti-HBsAg coated on the membrane.

**Precautions**

- For professional in vitro diagnostic use only. Do not use after expiration date.
- Do not eat, drink or smoke in the area where the specimens and kits are handled.
- Handle all specimens as if they contain infectious agents. Observe established precautions against microbiological hazards throughout the procedure and follow the standard procedures for proper disposal of specimens.
- Wear protective clothing such as laboratory coats, disposable gloves and eye protection when specimens are assayed.
- Humidity and temperature can adversely affect results.

**Storage and Stability**

The kit can be stored at room temperature or refrigerated (2-30°C). The test device is stable through the expiration date printed on the sealed pouch. The test device must remain in the sealed pouch until use. DO NOT FREEZE. Do not use beyond the expiration date.

**Specimen collection and Preparation**

- The QuickStripe™ Hepatitis B can be performed using either serum or plasma.
- Separate the serum or plasma from blood as soon as possible to avoid hemolysis. Only clear, non-hemolyzed specimens can be used.
- Testing should be performed immediately after the specimens have been collected. Do not leave the specimens at room temperature for prolonged periods. Specimens may be stored at 2-8°C for up to 3 days. For long term storage, specimens should be kept below -20°C.
- Bring specimens to room temperature prior to testing. Frozen specimens must be completely thawed and mixed well prior to testing. Specimens should not be frozen and thawed repeatedly.
- If specimens are to be shipped, they should be packed in compliance with federal, state or local regulations for the transportation of etiologic agents.

**Materials**

- Test devices
- Disposable specimen droppers
- Package insert

**Materials Required But Not Provided**

- Specimen collection container
- Centrifuge (for plasma only)
- Timer

**Directions For Use**

Allow test device, serum or plasma specimen, and/or controls to equilibrate to room temperature (15-30°C) prior to testing.
1. Bring the pouch to room temperature before opening it. Remove the test device from the sealed pouch and use it as soon as possible. Best results will be obtained if the assay is performed within one hour.

2. Place the test device on a clean and level surface. Hold the dropper vertically and transfer 3 full drops of serum or plasma (approx. 100µl) to the specimen well (S) of the test device, and then start the timer. Avoid trapping air bubbles in the specimen well (S). See the illustration below.

3. Wait for the red line(s) to appear. The result should be read at 15 minutes.

   Note: A low HBsAg concentration might result in a weak line appearing in the test region (T) after an extended period of time; therefore, do not interpret the result after 30 minutes.

   ![Illustration of test device]

**Interpretation of Results**

(Please refer to the illustration above)

**POSITIVE: Two distinct red lines appear.** One line should be in the control region (C) and another line should be in the test region (T).

**NOTE:** The intensity of the red color in the test line region (T) will vary depending on the concentration of HBsAg present in the specimen. Therefore, any shade of red in the test region (T) should be considered positive.

**NEGATIVE: One red line appears in the control region (C).** No apparent red or pink line appears in the test region (T).

**INVALID:** Control line fails to appear. Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for control line failure. Review the procedure and repeat the test with a new test device. If the problem persists, discontinue using the test kit immediately and contact your local distributor.

**Quality Control**

A procedural control is included in the test. A red line appearing in the control region (C) is the internal procedural control. It confirms sufficient specimen volume and correct procedural technique. Control standards are not supplied with this kit; however, it is recommended that a positive control (containing 10 ng/mL HBsAg) and a negative control control (containing 0 ng/mL HBsAg) be tested as a good laboratory practice to confirm the test procedure and to verify proper test performance.

**Limitation**

1. The QuickStripe™ Hepatitis B is for in vitro diagnostic use only. This test should be used for the detection of HBsAg in serum or plasma specimen.

2. The QuickStripe™ Hepatitis B will only indicate the presence of HBsAg in the specimen and should not be used as the sole criteria for the diagnosis of Hepatitis B viral infection.

3. As with all diagnostic tests, all results must be considered with other clinical information available to the physician.

4. The QuickStripe™ Hepatitis B cannot detect less than 1 ng/mL of HBsAg in specimens. If the test result is negative and clinical symptoms persist, additional follow-up testing using other clinical methods is suggested. A negative result at any time does not preclude the possibility of Hepatitis B infection.

**Expected Values**

The QuickStripe™ Hepatitis B has been compared with a leading commercial HBsAg EIA test. The correlation between these two systems is over 98%.

**Performance Characteristics**

**Sensitivity**

The QuickStripe™ Hepatitis B has been tested with a sensitivity panel ranging from 0 to 300 ng/mL. All 10 HBsAg subtypes produced positive results on the HBsAg One Step Hepatitis B Surface Antigen Test Device (Serum/Plasma). The test can detect 5ng/mL of HBsAg in 15 minutes, and 1 ng/mL of HBsAg in 30 minutes.

**Specificity**

Antibodies used for the QuickStripe™ Hepatitis B were developed against whole Hepatitis B antigen isolated from Hepatitis B virus. Specificity of the QuickStripe™ Hepatitis B was also tested with laboratory strains of Hepatitis A and Hepatitis C. They all yielded negative results.

**HBsAg Reference Method**

<table>
<thead>
<tr>
<th>Method</th>
<th>EIA Total Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>HBsAg Test Device</td>
<td>Results</td>
</tr>
<tr>
<td>Positive</td>
<td>145</td>
</tr>
<tr>
<td>Negative</td>
<td>150</td>
</tr>
</tbody>
</table>

Relative Sensitivity: > 99.0%
Relative Specificity: 96.7%
Accuracy: 98.3%

**Precision**

**Intra-Assay**

Within-run precision has been determined by using 15 replicates of three specimens containing 0 ng/mL, 1 ng/mL and 5 ng/mL of HBsAg. The negative and positive values were correctly identified 98% of the time.

**Inter-Assay**

Between-run precision has been determined by using the same three specimens of 0 ng/mL, 1 ng/mL and 5 ng/mL of HBsAg in 15 independent assays. Three different lots of the QuickStripe™ Hepatitis B have been tested over a 3-month period using negative, low positive and high positive specimens. The specimens were correctly identified 98% of the time.

**Bibliography**